Abstract

BackgroundMelanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process.ResultsTo decipher the genetics of these melanomas, we sequence the protein coding exons of 53 primary melanomas generated from several BRAFV600E or NRASQ61K driven transgenic zebrafish lines. We find that engineered zebrafish melanomas show an overall low mutation burden, which has a strong, inverse association with the number of initiating germline drivers. Although tumors reveal distinct mutation spectrums, they show mostly C > T transitions without UV light exposure, and enrichment of mutations in melanogenesis, p53 and MAPK signaling. Importantly, a recurrent amplification occurring with pre-configured drivers BRAFV600E and p53-/- suggests a novel path of BRAF cooperativity through the protein kinase A pathway.ConclusionThis is the first analysis of a melanoma mutational landscape in the absence of UV light, where tumors manifest with remarkably low mutation burden and high heterogeneity. Genotype specific amplification of protein kinase A in cooperation with BRAF and p53 mutation suggests the involvement of melanogenesis in these tumors. This work is important for defining the spectrum of events in BRAF or NRAS driven melanoma in the absence of UV light, and for informed exploitation of models such as transgenic zebrafish to better understand mechanisms leading to human melanoma formation.

Highlights

  • Melanoma is the most deadly form of skin cancer

  • We sought to build upon these studies through a focused analysis of a set of engineered melanomas, to determine the spectrum of mutations in the absence of UV light and to interrogate the role of BRAF, NRAS and p53 in melanoma in transgenic zebrafish

  • Transgenic individuals with BRAF;p53-/-;mitf -/- were manipulated with a miniCoopR shuttle vector system [18], consisting of somatic mosaic rescue of MITF expression in melanocytes along with SETDB1 [18] and transcription factors KROX20, FOXD3 or OCT6, the biology and oncogenicity of which are being investigated independently

Read more

Summary

Introduction

Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process. Activating mutations in BRAF (V600E) or NRAS (Q61K) are collectively found in approximately 60% of human melanomas and result in the constitutive signaling of the mitogen-activated protein kinase (MAPK) pathway [2,3]. Recent analyses of the genomes and exomes of human melanoma have resulted in the identification of new mutations that are likely to contribute to the disease formation or survival [7,8,9,10,11]. Our analysis reveals striking genetic heterogeneity, genotype-specific mutation patterns and a potential novel path to BRAFdriven tumorigenesis, providing insights into the events important for cooperation with BRAF and NRAS in the context of low mutation burden

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call